Pretreatment ALI was a significant independent predictor of early progression in advanced NSCLC patients receiving nivolumab. This may be useful for clinical decision making by identifying patients who may benefit from continued nivolumab treatment.

Circulating miR-18a, miR-20a, and miR-92a levels may serve as novel and promising prognostic biomarkers in patients with non-small cell lung cancer.

Since both atrial fibrillation and cancer are common, any increased risk of complications among patients treated with vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) may have major public health implications. This study found that the absolute risks of thromboembolic or bleeding complications were nearly the same in patients with and without cancer who redeemed prescriptions for VKAs or NOACs.

Combination of PD-L1 and CD8⁺ TILs density may suggest impressive prognostic value in NSCLC patients instead of PD-L1 alone. Less than half of patients with resected NSCLC experienced inconsistent PD-L1 expression between primary and metastatic lesions, and significance of PD-L1 expression in a single-biopsy specimen in advanced NSCLC may be overestimated in clinical practice.

A total of 308 circRNAs, including 107 (34.74%) up-regulated and 201 (65.26%) down-regulated circRNAs, were found significantly aberrantly expressed in gastric cancer tissues. The hot-point chromosomes were chr1, chr2, chr3, chr9, and chr17. Some circRNAs including hsa_circ_0014717 can stably exist in human body fluid, and has the potential to be used as novel biomarkers for the screen of high-risk gastric cancer patients.

GPC1 protein expression was associated with poor prognosis in PDAC.

PD-L1-expressing NSCLC had a high glucose metabolism. The SUVmax in preoperative 18F-FDG PET/CT was a predictor of PD-L1 protein expression in patients with NSCLC.

The overexpression of miR-497 is significantly correlated with temozolomide resistance in glioma cells by regulating mammalian target of rapamycin (mTOR)/Bcl-2, and miR-497 may be used as a new target for treatment of chemotherapy-resistant glioma.

Pancreatic cancer-associated fibroblasts (CAFs) promote M2 polarization of macrophages by increasing ROS production. M-CSF secreted by CAF contribute to the enhanced ROS production and M2 polarization. CAF-induced M2 macrophages promote growth and migration of pancreatic tumor cells.

LncRNA TUG1 expression was significantly upregulated in cervical cancer and correlated with tumor size, international federation of gynecology and obstetrics (FIGO) stage, cell differentiation, and lymph node metastasis. Knockdown of TUG1 expression in cervical cancer cells inhibited cell proliferation and promoted cell apoptosis. Knockdown of TUG1 expression inhibited migration and invasion of cervical cancer cells via the mechanism of epithelial–mesenchymal transition (EMT).

Our study demonstrates the feasibility and sensitivity of detecting epidermal growth factor receptor (EGFR) T790M status in plasma samples from NSCLC patients with acquired EGFR-TKI resistance. The ddPCR assay detecting in plasma ctDNA T790M may provide an alternative method in some situations. Patients with acquired T790M mutation at the time of progression have gradual progression compared to those without T790M mutation. And T790M-positive patients have better clinical outcomes to EGFR-TKIs than T790M-negative patients.

The combination of nivolumab and ipilimumab is a highly effective treatment for patients with melanoma, and little is known about the patients who do the best after treatment. For the first time, we report basic clinical laboratory variables which are associated with overall survival following treatment.

lncRNAs are emerging as critical regulators that are involved in the development and progression of cancers in humans. We comprehensively investigated lncRNA expression profiling in HCC and normal tissues; these findings may provide a valuable resource to further identify novel biomarkers and therapeutic targets of HCC.

MSI-H status can be determined by NGS across cancer types without requiring a matched tissue sample. MSI-H offers distinct data for treatment decisions regarding immune checkpoint inhibitors, in addition to the data available from TMB and PD-L1.

miR-206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9. These data indicated that miR-206 plays its anti-HCC effect via, at least partially, targeting the CDK9 signaling pathway, suggesting that miR206-CDK9 pathway may be a novel potential target for the treatment of HCC.

Pretreatment Glasgow prognostic score (GPS), NLR, platelet-lymphocyte ratio (PLR), LMR of 388 nasopharyngeal carcinoma (NPC) patients who were recruited prospectively in the 863 Program No. 2006AA02Z4B4 were assessed. After multivariate analysis of the 249 patients of the development set, age, T stage, N stage, and GPS, NLR, LMR appeared to be independent prognostic factors of 5-year disease-specific survival (DSS), and a nomogram was established to predict the DSS based on these factors. The model was validated in 139 patients of the validation set.

CA1 promoted CREB1 expression by regulating miR-590-3p expression in gastric cancer